WJ 01024
Alternative Names: JS110; WJ1024; WJ1075Latest Information Update: 16 Sep 2022
At a glance
- Originator Wigen Biomedicine
- Developer Shanghai Junshi Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Exportin 1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Malignant melanoma
Most Recent Events
- 25 Aug 2022 US FDA approves IND application for JS 110 in Solid tumours
- 30 Aug 2021 Preclinical trials in Malignant melanoma in China (PO) (Shanghai Junshi Biosciences pipeline, August 2021)
- 16 Sep 2020 WJ 1024 licensed to Junshi Biosciences worldwide for the treatment of Solid tumours and Haematological malignancies